



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

Neovacs to present at two major Investor Conferences:

The 18th Annual Rodman & Renshaw Global Investment Conference
&
Bio Europe 2016

Paris and Boston, August 30, 2016 – Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced CEO Miguel Sieler will present at the [18th Annual Rodman & Renshaw Global Investment Conference](#) and [Bio Europe 2016](#).

The Rodman & Renshaw Global Investment Conference, being held September 11-13 in New York, NY, will host over 265 public and private companies, and several thousand attendees. The conference will bring together a vast audience of financial and strategic investors with growth companies in the fields of healthcare, natural resources, technology, media and telecommunications, and cleantech. In addition to corporate presentations, the conference facilitates one-on-one meetings with members of the investment community.

Miguel Sieler, CEO of Neovacs, will present the company at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am ET at the New York Palace Hotel, on the fourth floor in the Louis Room.

Neovacs will also present at Bio Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world's most important meeting for the biotech Industry. This year Bio Europe event will draw over 3,500 attendees from 60 countries, representing 1,800 companies. It will provide Neovacs with the opportunity to meet with a vast audience of financial and strategic investors, as well as potential high-level partners.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com

Investor Relations / Financial Communication Germany – MC Services

Raimund Gabriel

+49-89-21-02-28-30

raimund.gabriel@mc-services.eu

Press / U.S. Inquiries – The Ruth Group

Lee Roth / Joseph Green

+1-646-536-7012 / 7013

lroth@theruthgroup.com / jgreen@theruthgroup.com